Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Feb;83(2):329-32.
doi: 10.1111/j.1365-2249.1991.tb05637.x.

Induction of tumour necrosis factor-alpha during haemodialysis. Influence of the membrane type

Affiliations

Induction of tumour necrosis factor-alpha during haemodialysis. Influence of the membrane type

S Chollet-Martin et al. Clin Exp Immunol. 1991 Feb.

Abstract

Some of the secondary clinical effects induced by long-term haemodialysis in patients with end-stage renal failure have been related to an increased production of interleukin-1 (IL-1). We investigated the role of another cytokine which shares a number of biological properties with IL-1, tumour necrosis factor-alpha (TNF-alpha). In long-term haemodialysed patients, we found at the beginning of the dialysis increased plasma TNF-alpha levels and enhanced monocyte capacity to produce TNF-alpha spontaneously ex vivo. Non-haemodialysed uraemic patients also presented increased plasma TNF-alpha levels. During dialysis with cellulose acetate (CA) or polysulphone (PS) membranes, plasma TNF-alpha levels and the spontaneous and lipopolysaccharide-induced production of TNF-alpha by monocytes remained at predialysis levels. In contrast, when cuprophane membranes were used, there was a significant increase in plasma TNF-alpha levels and in both spontaneous (10-fold) and lipopolysaccharide-induced (seven-fold) ex vivo TNF-alpha production by monocytes. These results suggest that monocytes are stimulated during haemodialysis with the poorly biocompatible cuprophane membrane.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol Methods. 1977;14(3-4):267-9 - PubMed
    1. Eur J Immunol. 1990 Feb;20(2):253-7 - PubMed
    1. Am J Nephrol. 1986;6(2):81-91 - PubMed
    1. J Exp Med. 1986 Jun 1;163(6):1433-50 - PubMed
    1. Lancet. 1987 Jan 3;1(8523):14-6 - PubMed